Chiquita Brooks-LaSure, the administrator for the Centers of Medicare and Medicaid Services (AP Photo/Evan Vucci)
CMS explains how it will negotiate the most expensive drug prices with biopharma beginning in 2026
The Centers for Medicare and Medicaid Services (CMS) late Wednesday published its first long-awaited guidance on how exactly biopharma companies will have to negotiate with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
